Saturday, October 29, 2016 Cincinnati, Ohio

The American Board of Psychiatry and Neurology has reviewed the 2016 Psychopharmacology Update and has approved this program as part of a comprehensive CME program, which is mandated by the ABMS as a necessary component of maintenance of certification (MOC). The activity awards 7.5 AMA PRA Category 1 CreditsTM and 8 Self-Assessment Category 1 CME credits.

Overview of the 15th Annual Psychopharmacology Update

This well-established one-day CME symposium offers an outstanding opportunity for education and networking with minimal disruption to your busy schedule. At this full-day course, nationally renowned faculty will cover Psychiatric Pharmacotherapies: Controversies, Evidence and Best Practices. You will get in-depth analysis from our expert faculty and ample time to query them on topics that will help keep your practice ahead of the curve.

Who Should Attend
The 2016 Psychopharmacology Update is a CME conference designed for child and adolescent psychiatrists, general psychiatrists, geriatric psychiatrists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with psychiatric disorders to remission with measurement based care

Continuing Medical Education

Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education, Inc. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 7.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants Credit Designation
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.
This activity is endorsed by Current Psychiatry.
Learning Objectives
At the conclusion of this activity, participants should be able to:
  • Discuss the pros and cons of various pharmacotherapeutic options in depression, schizophrenia, bipolar disorders, ADHD and child and adolescent psychiatric disorders.
  • Discuss evidence-based strategies for treating youth at familial risk for developing bipolar disorder.
  • Identify relative outcomes after augmentation versus switching strategies in treatment-resistant depression.
  • Describe the evidence base involving the short- and long-term efficacy versus safety risks of antidepressants in patients with bipolar depression.
  • Differentiate bipolar disorder from ADHD even when they co-exist.
  • Discuss data relevant to the therapeutic profile of lithium vs. anticonvulsants in the treatment of bipolar disorder.